Kytopen announces expansion of its partnership program into Europe with its agreement with T-CURX GmbH, a biotech company based in Würzburg, Germany. T-CURX, a clinically focused therapeutic company ...
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...
AZoLifeSciences on MSN2d
Gene Delivery Systems: Viral vs. Non-Viral VectorsThis article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...
No cardiac tests were ordered, and he was sent home with a steroid prescription that likely worsened his condition. Not only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback